Evidence map›Paper›PMID 41144542›Full record

ArticlePloS one2025

Sequencing and analysis of 131 SARS-CoV-2 isolates in previously sampled and unsampled regions of Jordan from 2020 to 2023.

Rame Khasawneh, Andrew W Bartlow, Shirin Almharat, Abdullah Almuhasen, Ali Alhuniti, Lena Hajaya, Al Anood Al Habashneh, Osama Alshudefat, Mohammad Dojan, Abdelghani Tbakhi and 5 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rame KhasawnehRoyal Medical Services Military Cancer Center, Amman, Jordan.
Andrew W BartlowLos Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Shirin AlmharatRoyal Medical Services Military Cancer Center, Amman, Jordan.
Abdullah AlmuhasenRoyal Medical Services Military Cancer Center, Amman, Jordan.
Ali AlhunitiRoyal Medical Services Military Cancer Center, Amman, Jordan.
Lena HajayaRoyal Medical Services Military Cancer Center, Amman, Jordan.
Al Anood Al HabashnehRoyal Medical Services Military Cancer Center, Amman, Jordan.
Osama AlshudefatRoyal Medical Services Military Cancer Center, Amman, Jordan.
Mohammad DojanRoyal Medical Services Military Cancer Center, Amman, Jordan.
Abdelghani TbakhiMcMaster University Medical Centre, Ontario, Canada.
Zeena ShaheenKing Hussein Cancer Center, Amman, Jordan.
Eiad AtwaKing Hussein Cancer Center, Amman, Jordan.
Colin Ps KruseLos Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
Osama AlsmadiKing Hussein Cancer Center, Amman, Jordan.
Samuel I KoehlerLos Alamos National Laboratory, Los Alamos, New Mexico, United States of America.ORCID https://orcid.org/0000-0002-8500-1824

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Hashemite Kingdom of Jordan remains an understudied country for next generation sequencing analysis of SARS-CoV-2 genomes collected during the 2019 pandemic. Here we provide 131 additional reference genomes collected between 2020-2023 from SARS-CoV-2-positive patients across Jordan. Phylogenetic analysis supports existing pandemic narratives of changing clade dominance over time and adds genomes in novel Jordanian locations and timepoints to make Jordan SARS-CoV-2 databases more comprehensive. Samples from the less-sequenced cities of Ajloun, Jaresh, Karak, and Madaba identified previously unreported lineages while Amman, Irbid, and Zarqa have existing sequencing efforts bolstered. Despite many incomplete patient records and a relatively small sample size, we observe interesting symptom patterns that support existing global and Jordanian pandemic narratives. We note how in-country COVID-19 pandemic genomic studies showcase Jordan's efforts to expand next generation sequencing capabilities, especially through the leveraging of EDGE COVID-19, a bioinformatics platform for performing rapid, batched analysis of SARS-CoV-2 sequencing that streamlines sample processing prepared from a network of hospital locations.

Indexed as

COVID-19SARS-CoV-2FemaleGenome, ViralHigh-Throughput Nucleotide SequencingHumansJordanMalePandemicsPhylogeny

Identifiers

PMID41144542
PMCPMC12558501

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.